Biosimilars

Dr. Reddy’s Stock Analysis 2026: Q3 Profit Dips 14% – Opportunity or Trap? Introduction: Indian Pharma sector ka heavy-weight, Dr. Reddy’s Laboratories, filhal do alag dishaon me chal raha hai. Ek taraf India aur Emerging Markets me shandaar growth hai, wahi dusri taraf America (US) me pricing pressure ne munafa nichod diya hai. 21 January … Read more